Mercer Global Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $137M | Buy |
543,313
+70,669
| +15% | +$15.2M | 0.17% | 76 |
|
|
2026
Q1 | $103M | Buy |
472,644
+42,013
| +10% | +$9.32M | 0.15% | 83 |
|
|
2025
Q4 | $100M | Buy |
430,631
+23,859
| +6% | +$5.44M | 0.15% | 89 |
|
|
2025
Q3 | $94.2M | Sell |
406,772
-160,307
| -28% | -$32.6M | 0.16% | 84 |
|
|
2025
Q2 | $105M | Buy |
567,079
+235,490
| +71% | +$43.8M | 0.21% | 65 |
|
|
2025
Q1 | $68.9M | Sell |
331,589
-2,892
| -0.9% | -$562K | 0.16% | 79 |
|
|
2024
Q4 | $59.4M | Sell |
334,481
-21,316
| -6% | -$3.92M | 0.15% | 83 |
|
|
2024
Q3 | $70.1M | Sell |
355,797
-130,228
| -27% | -$24.3M | 0.16% | 84 |
|
|
2024
Q2 | $56.9M | Buy |
486,025
+169,211
| +53% | +$28M | 0.16% | 87 |
|
|
2024
Q1 | $57.8M | Buy |
316,814
+23,042
| +8% | +$3.97M | 0.16% | 88 |
|
|
2023
Q4 | $45.5M | Buy |
293,772
+3,499
| +1% | +$510K | 0.14% | 108 |
|
|
2023
Q3 | $43.3M | Sell |
290,273
-10,812
| -4% | -$1.59M | 0.16% | 84 |
|
|
2023
Q2 | $40.6M | Sell |
301,085
-12,247
| -4% | -$1.8M | 0.16% | 95 |
|
|
2023
Q1 | $49.9M | Sell |
313,332
-4,726
| -1% | -$723K | 0.23% | 74 |
|
|
2022
Q4 | $51.4M | Buy |
318,058
+510
| +0.2% | +$78.2K | 0.26% | 65 |
|
|
2022
Q3 | $42.6M | Buy |
317,548
+873
| +0.3% | +$125K | 0.25% | 65 |
|
|
2022
Q2 | $48.5M | Buy |
316,675
+13,665
| +5% | +$2.09M | 0.3% | 58 |
|
|
2022
Q1 | $49.1M | Buy |
303,010
+6,491
| +2% | +$943K | 0.29% | 55 |
|
|
2021
Q4 | $40.1M | Buy |
296,519
+10,276
| +4% | +$1.21M | 0.25% | 67 |
|
|
2021
Q3 | $30.9M | Buy |
286,243
+27,426
| +11% | +$3.13M | 0.22% | 77 |
|
|
2021
Q2 | $29.2M | Buy |
258,817
+12,764
| +5% | +$1.44M | 0.22% | 78 |
|
|
2021
Q1 | $26.6M | Buy |
246,053
+60,574
| +33% | +$6.48M | 0.24% | 70 |
|
|
2020
Q4 | $19.9M | Sell |
185,479
-41
| -0% | -$3.94K | 0.25% | 64 |
|
|
2020
Q3 | $16.3M | Buy |
185,520
+7,569
| +4% | +$713K | 0.24% | 67 |
|
|
2020
Q2 | $17.5M | Buy |
177,951
+74,541
| +72% | +$6.56M | 0.32% | 55 |
|
|
2020
Q1 | $7.88M | Sell |
103,410
-16,588
| -14% | -$1.41M | 0.17% | 107 |
|
|
2019
Q4 | $10.6M | Sell |
119,998
-319
| -0.3% | -$26.5K | 0.21% | 95 |
|
|
2019
Q3 | $9.11M | Buy |
120,317
+9,850
| +9% | +$675K | 0.21% | 95 |
|
|
2019
Q2 | $8.03M | Buy |
110,467
+13,427
| +14% | +$1.06M | 0.21% | 97 |
|
|
2019
Q1 | $7.82M | Buy |
+97,040
| New | +$7.94M | 0.28% | 67 |
|
Other funds holding ABBV
Mercer Global Advisors's ABBV Position: Q2 2026 in Review
Mercer Global Advisors increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $15.2M and bringing the position to 543,313 shares worth $137M. The position accounts for 0.17% of the portfolio, ranked #76.
Mercer Global Advisors first reported a position in ABBV in Q1 2019 and has held it in 30 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Mercer Global Advisors held 543,313 shares of AbbVie worth $137M as of Q2 2026.
- Mercer Global Advisors bought 70,669 AbbVie shares in Q2 2026, an estimated $15.2M.
- AbbVie made up 0.17% of Mercer Global Advisors's portfolio in Q2 2026, its #76 holding.
- Mercer Global Advisors first reported a position in AbbVie in Q1 2019 and has held it in 30 quarters since.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.